When the relationship between ANKRD49 expression and clinicopathological parameters of LUAD was assessed, it was found that ANKRD49 expression was markedly higher in advanced stages of tumour development, including stages III and IV (p = 0.006) of the tumour, node, and metastasis (TNM) staging system for lung cancer, lymph node metastasis (p = 0.022), distant metastasis (p = 0.025), and differentiation (p = 0.006), compared to early stages of tumour development, including TNM stages I and II, and metastasis without lymph node (Table 1). This evidence concerns the gene ANKRD49 and lung carcinoma.